AAD 2026Abstract 72329
The use of topical ruxolitinib in the treatment of localized, steroid-refractory cutaneous immune-related adverse events
A single-institution real-life study
Block B, Mehta J, Karpoff K, Verma H, Lambert R, Rabinowitz G, Young J, Powers C, Gulati N
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Drug reactions
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.1780 · Not in PubMed: details from Crossref